Dose proportionality and half‐life of tenofovir in hair samples from those with differing adherence to TDF or TAF‐based regimens monitored by directly observed therapy

Documenti analoghi

• TFV‐DP adherence interpretations from TDF using an updated 50% methanol and 50% water extraction method for DBS
  Pubblicazione: (2024)
• Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pregnant women with HIV
  Pubblicazione: (2024)
• Physicochemical stability of DELSTRIGO®: A combination of three active substances (tenofovir disoproxi fumarate [TDF], lamivudine [3TC] doravirine [DOR]) in the management of occupational in the management of HIV post‐exposure prophylaxis (PEP)
  di: E. Hindes, et al.
  Pubblicazione: (2025)
• No observed bidirectional effect between tenofovir diphosphate concentrations and gender‐affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre‐exposure prophylaxis
  di: Nimish Patel, et al.
  Pubblicazione: (2024)
• Longitudinal monitoring of cabotegravir and rilpivirine exposure from hair strand concentrations
  di: E. Rosen, et al.
  Pubblicazione: (2025)